GlycoMimetics (GLYN) is a development-stage biotechnology company focused on cancer and sickle cell disease. The firm’s most advanced drug, rivipansel, a pan-selectin antagonist, is being developed for vaso-occlusive crisis in sickle cell disease. The product is in a Phase 3 clinical trial being conducted by GlycoMimetics’ strategic collaborator, Pfizer.
But the recent news is about GlycoMimetics’ wholly-owned drug candidate, GMI-1271, an E-selectin antagonist, is being evaluated in an ongoing Phase 1/2 clinical trial as a potential treatment for acute myeloid leukemia (AML) and in a Phase 1 clinical trial in multiple myeloma.
GlycoMimetics has also recently initiated a clinical trial with a third drug candidate, GMI-1359, a combined C-X-C chemokine receptor type 4 (CXCR-4) and E-selectin antagonist.
GlycoMimetics resides in Rockville, MD in the BioHealth Capital Region.
Recent NEWS
GlycoMimetics’ drug GMI-1271 demonstrated high overall response rates, low induction mortality, promising initial survival outcomes, and supportive biomarker data from phase 1/2 trial for the treatment of acute myeloid leukemia (AML).
The firm released abstracts containing new data from the ongoing Phase 2 clinical trial of its product candidate GMI-1271, an E-selectin antagonist, in patients with acute myeloid leukemia (AML). The data will be presented at the June annual meetings of the American Society of Clinical Oncology (ASCO) and the European Hematology Association (EHA). The data, which were revealed revealed by the firm demonstrated high overall response rates, low induction mortality, promising initial survival outcomes, and supportive biomarker data.
Observations:
– In the relapsed/refractory cohort, patients with higher levels of the E-selectin ligand biomarker on their leukemic blasts appear to be more likely to achieve remission of their disease.
– The expression of E-selectin ligand biomarker on leukemia cells supports the mechanism of action of GMI-1271.
– The drug was well tolerated with no evident toxicity when the GMI-1271 product is added to chemotherapy.
– AML patients treated with GMI-1271 combined with chemotherapy, continued to experience higher-than-expected remission rates and lower-than-expected induction-related mortality rates in both arms of the trial.
– The firm is increasingly confident that GMI-1271 may play a role in an unmet need in AML.
Prohost Observations
GlycoMimetics, no doubt, is creative. The good news about its creativity is that it is yielding new promising results from its wholly-owned AML and multiple myeloma E-selectin antagonist drug GMI-1271. It is also showing good results from the most advanced pan-selectin antagonist drug, rivipansel, in Phase 3 trial for vaso-occlusive crisis in sickle cell disease. Pfizer, the firm’s strategic collaborator is developing the product.
As observed from the above article, AML patients with higher levels of the E-selectin ligand biomarker on their leukemic blasts appear more likely achieve remission of their disease.
Also the expression of E-selectin ligand biomarker on leukemia cells validates GMI-1271 mechanism of action.
We tend to agree with GlycoMimetics that its drugs will play a substantial role in the treatment of various diseases.
Our minds are prepared to digest more details that we expect the firm will include in the several abstracts it will present at the ASCO 2017.
*********** ********** **********
Expect Prohost Letter #409 to be posted very soon. This new issue is mostly about the ASCO presentations as well as other Prohost picked companies, especially those having important news
Prohost Forward-Looking: Material presented here is for informational purposes only. Nothing in this article should be taken as a solicitation to purchase or sell securities. Before buying or selling any stock you should do your own research and reach your own conclusion. Further, these are our ‘opinions’ and we may be wrong. We may have positions in securities mentioned in this article. You should take this into consideration before acting on any advice given in this article. If this makes you uncomfortable, then do not listen to our thoughts and opinions. The contents of this article do not take into consideration your individual investment objectives so consult with your own financial adviser before making an investment decision. Investing includes certain risks including loss of principal
GlycoMimetics: A Lot to Tell at the ASCO Meeting
GlycoMimetics (GLYN) is a development-stage biotechnology company focused on cancer and sickle cell disease. The firm’s most advanced drug, rivipansel, a pan-selectin antagonist, is being developed for vaso-occlusive crisis in sickle cell disease. The product is in a Phase 3 clinical trial being conducted by GlycoMimetics’ strategic collaborator, Pfizer.
But the recent news is about GlycoMimetics’ wholly-owned drug candidate, GMI-1271, an E-selectin antagonist, is being evaluated in an ongoing Phase 1/2 clinical trial as a potential treatment for acute myeloid leukemia (AML) and in a Phase 1 clinical trial in multiple myeloma.
GlycoMimetics has also recently initiated a clinical trial with a third drug candidate, GMI-1359, a combined C-X-C chemokine receptor type 4 (CXCR-4) and E-selectin antagonist.
GlycoMimetics resides in Rockville, MD in the BioHealth Capital Region.
Recent NEWS
GlycoMimetics’ drug GMI-1271 demonstrated high overall response rates, low induction mortality, promising initial survival outcomes, and supportive biomarker data from phase 1/2 trial for the treatment of acute myeloid leukemia (AML).
The firm released abstracts containing new data from the ongoing Phase 2 clinical trial of its product candidate GMI-1271, an E-selectin antagonist, in patients with acute myeloid leukemia (AML). The data will be presented at the June annual meetings of the American Society of Clinical Oncology (ASCO) and the European Hematology Association (EHA). The data, which were revealed revealed by the firm demonstrated high overall response rates, low induction mortality, promising initial survival outcomes, and supportive biomarker data.
Observations:
– In the relapsed/refractory cohort, patients with higher levels of the E-selectin ligand biomarker on their leukemic blasts appear to be more likely to achieve remission of their disease.
– The expression of E-selectin ligand biomarker on leukemia cells supports the mechanism of action of GMI-1271.
– The drug was well tolerated with no evident toxicity when the GMI-1271 product is added to chemotherapy.
– AML patients treated with GMI-1271 combined with chemotherapy, continued to experience higher-than-expected remission rates and lower-than-expected induction-related mortality rates in both arms of the trial.
– The firm is increasingly confident that GMI-1271 may play a role in an unmet need in AML.
Prohost Observations
GlycoMimetics, no doubt, is creative. The good news about its creativity is that it is yielding new promising results from its wholly-owned AML and multiple myeloma E-selectin antagonist drug GMI-1271. It is also showing good results from the most advanced pan-selectin antagonist drug, rivipansel, in Phase 3 trial for vaso-occlusive crisis in sickle cell disease. Pfizer, the firm’s strategic collaborator is developing the product.
As observed from the above article, AML patients with higher levels of the E-selectin ligand biomarker on their leukemic blasts appear more likely achieve remission of their disease.
Also the expression of E-selectin ligand biomarker on leukemia cells validates GMI-1271 mechanism of action.
We tend to agree with GlycoMimetics that its drugs will play a substantial role in the treatment of various diseases.
Our minds are prepared to digest more details that we expect the firm will include in the several abstracts it will present at the ASCO 2017.
*********** ********** **********
Expect Prohost Letter #409 to be posted very soon. This new issue is mostly about the ASCO presentations as well as other Prohost picked companies, especially those having important news
Prohost Forward-Looking: Material presented here is for informational purposes only. Nothing in this article should be taken as a solicitation to purchase or sell securities. Before buying or selling any stock you should do your own research and reach your own conclusion. Further, these are our ‘opinions’ and we may be wrong. We may have positions in securities mentioned in this article. You should take this into consideration before acting on any advice given in this article. If this makes you uncomfortable, then do not listen to our thoughts and opinions. The contents of this article do not take into consideration your individual investment objectives so consult with your own financial adviser before making an investment decision. Investing includes certain risks including loss of principal
Other Articles